华法林可降低循环白细胞数量:对两项随机试验的后期分析
Stefano Barco1, Christina Abele2, Walter Ageno3
1Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; Department of Angiology, University Hospital Zurich, Zurich, Switzerland.
Thrombosis research
|September 9, 2025
概括
华法林是一种维生素K抗剂 (VKA),在一项大型试验中与白细胞 (WBC) 和粒细胞的轻微减少有关. 这一发现支持了关于华法林的临床前数据.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 华法林是一种常见的维生素K抗剂 (VKA),表现出除了抗凝作用之外的作用.
- 临床前和病例控制研究表明,华法林可能会影响血液形成,但人类数据有限.
- 需要长度证据来证实华法林对血细胞生产的影响.
研究的目的:
- 为了研究华法林对血液形成的潜在影响.
- 分析用华法林治疗的患者与edoxaban治疗的患者白细胞 (WBC) 计数和亚群的变化.
主要方法:
- 从Hokusai-VTE和ENGAGE AF-TIMI 48个随机对照试验的数据进行了后期分析.
- 包括23,618名随机分配给华法林或爱多沙班的患者.
- 使用线性回归和混合效应模型分析总WBC和子群 (淋巴细胞,单细胞,粒细胞),调整共变量.
主要成果:
- 与edoxaban相比,华法林的使用与白细胞计数 (-2.3%) 和粒细胞计数 (-3.6%) 的统计显著减少有关.
- 华法林和埃多克萨班组之间在淋巴细胞或单细胞计数方面没有发现显著差异.
- 敏感性分析证实了这些关联,并且没有发现临床相关的粒细胞衰竭的风险增加.
结论:
- 华法林显示出微妙的血液学作用,特别是在粒细胞上,与临床前观察一致.
- 来自大型随机试验的这些发现表明,需要进一步研究VKA的长期血液形成效应.
- 观察到的对粒细胞的影响需要继续调查华法林对血液细胞动态的更广泛影响.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202


